Shares of Sana Biotechnology, Inc. (SANA) plummeted 11.84% on Friday, as traders took profits following the stock's massive rally over the past week on upbeat clinical study results.
SANA's stock skyrocketed 151.5% in the past week after the company announced positive initial data from a first-in-human study of its experimental type 1 diabetes cell therapy, UP421. In the study, UP421 was transplanted into a patient without the need for immunosuppression, thanks to Sana's proprietary hypoimmune (HIP) technology.
The results showed survival and functionality of the transplanted pancreatic beta cells, demonstrated by the presence of C-peptide, a biomarker indicating insulin production. Crucially, no safety concerns were identified, and the HIP-modified cells evaded immune responses, eliminating the need for chronic immunosuppression.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.